5 news items
Dynavax to Present at Upcoming Investor Conferences
DVAX
28 May 24
® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union
FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients
DVAX
14 May 24
for HEPLISAV-B in the U.S., the European Union, and Great Britain, which prevents infection caused by all known subtypes of hepatitis B virus
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
DVAX
14 May 24
of a four-dose regimen of HEPLISAV-B. The CRL has no impact on the approved indication for HEPLISAV-B in the U.S., the European Union
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
DVAX
8 May 24
]HEPLISAV-B vaccine is the first and only adult hepatitis B vaccine approved in the U.S., the European Union
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
DVAX
24 Apr 24
(Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great
- Prev
- 1
- Next